Search

Khrizstatin 40

Khrizstatin 40

atorvastatin

Manufacturer:

Celogen Generics

Distributor:

Khriz Pharma

Marketer:

Khriz Pharma
Concise Prescribing Info
Contents
Atorvastatin Ca
Indications/Uses
To reduce total-C & LDL-C in adults w/ HoFH as adjunct to other lipid-lowering treatments. Prevention of CV events in adults estimated to have a high risk for a 1st CV event.
Click to view Khrizstatin 40 detailed prescribing information
Dosage/Direction for Use
Individualized dosage. Initially 10 mg once daily. Dose adjustment should be made at intervals of ≥4 wk. Max: 80 mg once daily. Patient w/ heterozygous familial hypercholesterolemia ≥10 yr Initially 10 mg once daily, may be increased to 80 mg daily.
Click to view Khrizstatin 40 detailed prescribing information
Administration
May be taken with or without food: Avoid excessive consumption (>1 L/day) of grapefruit juice.
Contraindications
Hypersensitivity. Patients w/ active liver disease or unexplained persistent elevations of serum transaminases exceeding 3 x ULN. Women of childbearing potential not using appropriate contraceptive measures. Pregnancy & lactation.
Click to view Khrizstatin 40 detailed prescribing information
Special Precautions
Discontinue use if clinically significant elevation of CK levels (>10 x ULN) occur or if rhabdomyolysis is diagnosed or suspected; ILD is suspected to have developed. Patients who consume substantial quantities of alcohol &/or have history of liver disease; w/ prior hemorrhagic stroke or lacunar infarct; predisposing factors for rhabdomyolysis. Perform LFTs prior to initiation of treatment & periodically thereafter. DM. Contains lactose. Not to be taken by patients w/ galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Not indicated in childn <10 yr. Childn 6-10 yr w/ heterozygous familial hypercholesterolemia.
Click to view Khrizstatin 40 detailed prescribing information
Adverse Reactions
Nasopharyngitis; allergic reactions; hyperglycaemia; headache; pharyngolaryngeal pain, epistaxis; constipation, flatulence, dyspepsia, nausea, diarrhoea; myalgia, arthralgia, pain in extremity, muscle spasms, joint swelling, back pain.
Click to view Khrizstatin 40 detailed prescribing information
Drug Interactions
Plasma conc & risk of myopathy may be increased w/ CYP3A4 or transport protein inhibitors; other medicinal products w/ potential to induce myopathy eg, fibric acid derivates & ezetimibe. Concomitant use w/ CYP3A4 inhibitors. Variable reductions in plasma conc w/ CYP3A4 inducers eg, efavirenz, rifampin, St. John's wort. Increased systemic exposure w/ transport protein inhibitors eg, ciclosporin. May increase risk of muscle-related events including rhabdomyolysis w/ gemfibrozil/fibric acid derivatives; ezetimibe; systemic fusidic acid. Lowered plasma conc w/ colestipol. Myopathy w/ colchicine. Increased steady-state conc of digoxin. Increased plasma conc of norethindrone & ethinyl oestradiol. Decreased prothrombin time w/ warfarin.
Click to view Khrizstatin 40 detailed prescribing information
Storage
View Khrizstatin 40 storage conditions for details to ensure optimal shelf-life.
Description
View Khrizstatin 40 description for details of the chemical structure and excipients (inactive components).
Action
View Khrizstatin 40 mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Dyslipidaemic Agents
ATC Classification
C10AA05 - atorvastatin ; Belongs to the class of HMG CoA reductase inhibitors. Used in the treatment of hyperlipidemia.
Presentation/Packing
Form
Khrizstatin 40 FC tab 40 mg
Packing/Price
100's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in